Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofogliflozin and myocardial fibrosis in type 2 diabetes with NAFLD at risk for heart failure
jRCTs051220140Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of tofogliflozin in type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Indexed extracellular volume (iECV). Started Dec 2022; status: recruiting.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)heart failure (HF)
Beyond the preview
Go deeper on jRCTs051220140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220140.